Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUM7HZ)

Drug Name

Fluorouracil Drug Info

Synonyms

5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[1]
Colorectal cancer	2B91.Z	Investigative	[2]
Tumour	2A00-2F9Z	Investigative	[3]

Therapeutic Class

Immunosuppressive Agents

Cross-matching ID

PubChem CID: 3385
ChEBI ID: CHEBI:46345
CAS Number: CAS 51-21-8
TTD Drug ID: DMUM7HZ
VARIDT Drug ID: DR00153
INTEDE Drug ID: DR0020
ACDINA Drug ID: D01095

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

DME

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[22]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[23]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[24]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[25]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[27]
Oxaliplatin	DMQNWRD	Colorectal cancer	2B91.Z	Approved	[28]
Verapamil	DMA7PEW	Hypertension	BA00-BA04	Approved	[29]
Diclofenac	DMPIHLS	Osteoarthritis	FA00-FA05	Approved	[30]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Premature labour	JB00	Approved	[32]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[33]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[34]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[32]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[35]
Metronidazole	DMTIVEN	Amoebiasis	1A36	Approved	[36]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[37]
Nicotine	DMWX5CO	Nicotine dependence	6C4A.2	Approved	[38]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[32]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[39]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[39]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[32]
Verapamil	DMA7PEW	Hypertension	BA00-BA04	Approved	[40]
Diclofenac	DMPIHLS	Osteoarthritis	FA00-FA05	Approved	[41]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[42]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[39]
Mycophenolate mofetil	DMPQAGE	Organ transplant rejection	NE84	Approved	[43]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[37]
Ibuprofen	DM8VCBE	Pain	MG30-MG3Z	Approved	[44]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Methylenetetrahydrofolate reductase (MTHFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[45]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[46]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[47]
Benazepril	DMH1M9B	Hypertension	BA00-BA04	Approved	[48]
ISO-901	DMBQ8CA	Rheumatoid arthritis	FA20	Phase 1	[49]
------------------------------------------------------------------------------------

Drug(s) Metabolized By Thymidine phosphorylase (TYMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trifluridine	DMG2YBD	Virus infection	1A24-1D9Z	Approved	[50]
Capecitabine	DMTS85L	Colorectal cancer	2B91.Z	Approved	[51]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[52]
Deoxythymidine	DMR90HY	Discovery agent	N.A.	Investigative	[53]
------------------------------------------------------------------------------------

Drug(s) Metabolized By Thymidylate synthase (TYMS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[45]
2'-deoxyuridylic acid	DMPV1LU	Discovery agent	N.A.	Investigative	[54]
------------------------------------------------------------------------------------

Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[55]
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[56]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[57]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[58]
Cisplatin	DMRHGI9	Solid tumour/cancer	2A00-2F9Z	Approved	[59]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[60]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[61]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[62]
Oxaliplatin	DMQNWRD	Colorectal cancer	2B91.Z	Approved	[63]
Ampicillin	DMHWE7P	Bacterial infection	1A00-1C4Z	Approved	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Bacterial infection	1A00-1C4Z	Approved	[64]
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[65]
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[14]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[66]
Cisplatin	DMRHGI9	Solid tumour/cancer	2A00-2F9Z	Approved	[14]
Progesterone	DMUY35B	Premature labour	JB00	Approved	[67]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[14]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[68]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[70]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[71]
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[72]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[73]
Cisplatin	DMRHGI9	Solid tumour/cancer	2A00-2F9Z	Approved	[74]
Progesterone	DMUY35B	Premature labour	JB00	Approved	[75]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[76]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[75]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[77]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[78]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[79]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Organic anion transporter 2 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[80]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[81]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[82]
Erythromycin	DM4K7GQ	Bacterial infection	1A00-1C4Z	Approved	[83]
Aspirin	DM672AH	Myocardial infarction	BA41-BA43	Approved	[84]
Aciclovir	DMYLOVR	Virus infection	1A24-1D9Z	Approved	[85]
Ranitidine	DM0GUSX	Peptic ulcer	DA61	Approved	[86]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[87]
Theophylline	DMRJFN9	Chronic obstructive pulmonary disease	CA22	Approved	[83]
Tetracycline	DMZA017	Bacterial infection	1A00-1C4Z	Approved	[88]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Multidrug resistance-associated protein 3 (ABCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[89]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[90]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[91]
Ezetimibe	DM7A8TW	Hypercholesterolaemia	5C80.0	Approved	[92]
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[93]
Morphine	DMRMS0L	Chronic pain	MG30	Approved	[94]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[95]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[96]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[97]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[98]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Multidrug resistance-associated protein 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[99]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[100]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[101]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[64]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[102]
Irinotecan	DMP6SC2	Colorectal cancer	2B91.Z	Approved	[103]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[104]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[105]
Ganciclovir	DM1MBYQ	Virus infection	1A24-1D9Z	Approved	[64]
Cefazolin	DMPDYFR	Bacterial infection	1A00-1C4Z	Approved	[95]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Multidrug resistance-associated protein 5 (ABCC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[106]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[106]
Irinotecan	DMP6SC2	Colorectal cancer	2B91.Z	Approved	[107]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[108]
Ganciclovir	DM1MBYQ	Virus infection	1A24-1D9Z	Approved	[109]
Gemcitabine	DMSE3I7	Solid tumour/cancer	2A00-2F9Z	Approved	[110]
Fluorescein	DMQTFAO	Ocular disease	1F00.1Z	Approved	[111]
Pemetrexed	DMMX2E6	Malignant pleural mesothelioma	2C26.0	Approved	[112]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[113]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[114]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Equilibrative nucleoside transporter 1 (SLC29A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[115]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[117]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[118]
Clofarabine	DMCVJ86	Acute lymphoblastic leukaemia	2A85	Approved	[119]
Trifluridine	DMG2YBD	Virus infection	1A24-1D9Z	Approved	[120]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[121]
Tecadenoson	DM9T6MS	Atrial fibrillation	BC81.3	Discontinued in Phase 3	[122]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Drug(s) Targeting TERT messenger RNA (TERT mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
2,7-Bis(acetamido)anthraquinone	DM2EPM4	Discovery agent	N.A.	Investigative	[123]
2,7-Bis(cyclohexanecarbonamido)anthraquinone	DMTPZ8D	Discovery agent	N.A.	Investigative	[123]
2,7-Bis[2-(isopropylamino)acetamido]anthraquinone	DMRQGWX	Discovery agent	N.A.	Investigative	[123]
NSC-745884	DM8W0J3	Discovery agent	N.A.	Investigative	[124]
2,7-Bis[3-(piperidino)propionamido]anthraquinone	DMET693	Discovery agent	N.A.	Investigative	[123]
2,7-Bis(cyclopropanecarbonamido)anthraquinone	DMY3V2B	Discovery agent	N.A.	Investigative	[123]
2,7-Bis(phenylacetamido)anthraquinone	DMEVIBT	Discovery agent	N.A.	Investigative	[123]
NSC-745887	DMG9BWY	Discovery agent	N.A.	Investigative	[124]
2,7-Bis[2-(butylamino)acetamido]anthraquinone	DM3GTV0	Discovery agent	N.A.	Investigative	[123]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Candida Thymidylate synthase (Candi TMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciprofloxacin XR	DM2NLS9	Bacterial infection	1A00-1C4Z	Approved	[125]
Pemetrexed	DMMX2E6	Malignant pleural mesothelioma	2C26.0	Approved	[126]
Trifluridine	DMG2YBD	Virus infection	1A24-1D9Z	Approved	[127]
Capecitabine	DMTS85L	Colorectal cancer	2B91.Z	Approved	[128]
Raltitrexed	DMT9K8G	Rectal adenocarcinoma	2B92	Approved	[129]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[130]
Leucovorin/5-fluorouracil	DMZT4N7	Colon cancer	2B90.Z	Approved	[131]
Flucytosine	DM13VTW	Endocarditis	BB40-BA42	Approved	[132]
Nolatrexed	DMOF0CA	Solid tumour/cancer	2A00-2F9Z	Phase 3	[133]
Plevitrexed (R)-isomer	DMTL39C	Gastric adenocarcinoma	2B72	Phase 2	[134]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Dihydrothymine dehydrogenase (DPYD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eniluracil	DM96NCR	Hyperlipidaemia	5C80	Phase 2	[135]
RO-09-4889	DMQ65YW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[136]
FL-386	DMUQN83	Hyperlipidaemia	5C80	Discontinued in Phase 2	[137]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[138]
5-Iodouracil	DM4O6I5	Discovery agent	N.A.	Investigative	[138]
(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione	DMA5DO2	Discovery agent	N.A.	Investigative	[138]
6-Carboxymethyluracil	DM9MPDK	Discovery agent	N.A.	Investigative	[138]
Uracil	DMNPO9Q	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Drug(s) Targeting Thymidylate synthase messenger RNA (TYMS mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TS antisense + raltitrexed	DMIV75Q	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Thymidylate synthase (Candi TMP1)	TTU6BFZ	TYSY_CANAL	Inhibitor	[4] , [5] , [6] , [7]
Dihydrothymine dehydrogenase (DPYD)	TTZPS91	DPYD_HUMAN	Inhibitor	[8]
TERT messenger RNA (TERT mRNA)	TTQY2EJ	TERT_HUMAN	Not Available	[3]
Thymidylate synthase messenger RNA (TYMS mRNA)	TTP1UKZ	TYSY_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Equilibrative nucleoside transporter 1 (SLC29A1)	DTXD1TQ	S29A1_HUMAN	Substrate	[9]
Multidrug resistance-associated protein 5 (ABCC5)	DTYVM24	MRP5_HUMAN	Substrate	[10]
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[11]
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[10]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[12]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[10]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[13]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[15]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[15]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[15]
Thymidylate synthase (TYMS)	DEASG0Q	TYSY_HUMAN	Substrate	[16]
Methylenetetrahydrofolate reductase (MTHFR)	DEOXTPZ	MTHR_HUMAN	Substrate	[16]
Thymidine phosphorylase (TYMP)	DE4HCYL	TYPH_HUMAN	Substrate	[16]
Uridine phosphorylase 1 (UPP1)	DEFZWAX	UPP1_HUMAN	Substrate	[17]
Dihydrothymine dehydrogenase (DPYD)	DESOEW1	DPYD_HUMAN	Substrate	[18]
Uridine 5'-monophosphate synthase (UMPS)	DEWJYTE	UMPS_HUMAN	Substrate	[19]
Uracil phosphoribosyltransferase (UPRT)	DE20ETR	UPP_HUMAN	Substrate	[20]
Uridine phosphorylase 2 (UPP2)	DEBQ2WU	UPP2_HUMAN	Substrate	[17]
Amidophosphoribosyltransferase (GPAT)	DEMJ7R2	PUR1_HUMAN	Substrate	[21]

------------------------------------------------------------------------------------

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
4	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
5	Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to... J Cancer Res Clin Oncol. 2003 Dec;129(12):683-90.
6	Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J Histochem Cytochem. 2000 Jun;48(6):755-60.
7	Acquisition of resistance to anticancer agents by overproduction of target enzymes. Nippon Rinsho. 1997 May;55(5):1030-7.
8	Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7.
9	Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
10	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
11	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
12	Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
13	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
14	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
16	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
17	Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.
18	5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep. 2008 Mar-Apr;60(2):238-42.
19	Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Dis. 2016 Apr 5;4(1):e1165909.
20	Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther. 2000 Jul;7(7):1015-22.
21	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150653776)
22	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
23	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
24	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
25	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
26	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
27	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
28	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31	Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
32	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
33	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
34	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
35	Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
36	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
37	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
38	CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
39	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
40	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
41	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
42	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
43	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
44	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
45	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
46	Genetic variation: impact on folate (and choline) bioefficacy. Int J Vitam Nutr Res. 2010 Oct;80(4-5):319-29.
47	Purification and properties of 5,10-methylenetetrahydrofolate reductase, an iron-sulfur flavoprotein from Clostridium formicoaceticum. J Biol Chem. 1984 Sep 10;259(17):10845-9.
48	Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7.
49	Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40.
50	Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9.
51	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45.
52	Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008 Sep-Oct;5(5):717-27.
53	Thymidine catabolism as a metabolic strategy for cancer survival. Cell Rep. 2017 May 16;19(7):1313-1321.
54	Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J Biol Chem. 2002 Sep 27;277(39):36304-11.
55	Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
56	Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
57	Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
58	Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
59	Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
60	Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
61	Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
62	Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
63	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
64	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
65	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
66	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
67	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
68	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
69	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
70	Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
71	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
72	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
73	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
74	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
75	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
76	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
77	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
78	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
79	Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
80	Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
81	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
82	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
83	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
84	Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
85	Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
86	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
87	Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
88	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
89	Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
90	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
91	Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
92	Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
93	Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
94	Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
95	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
96	Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
97	Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
98	Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
99	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
100	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
101	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
102	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
103	P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
104	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
105	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
106	The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
107	Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
108	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13;3:732.
109	Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37(1):253-78.
110	Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
111	Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004.
112	Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
113	Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.
114	The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74.
115	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
116	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
117	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
118	Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet. 2013;28(5):406-10.
119	Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
120	Lonsurf, INN-trifluridine/tipiracil.
121	Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60.
122	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1. Drug Metab Dispos. 2013 Apr;41(4):916-22.
123	Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
124	Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
125	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
126	Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
127	Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
128	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
129	DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
130	Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
131	Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44.
132	Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
133	A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
134	Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
135	Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49.
136	Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35.
137	Effects of FL-386 on faecal lipid excretion in humans. J Int Med Res. 1993 Sep-Oct;21(5):225-33.
138	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.